Drug Profile


Alternative Names: Avodart; Avolve; GG 745; GI 198745

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiandrogens; Azasteroids; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase III Alopecia
  • Preregistration Submission Withdrawal Prostate cancer; Prostatic intraepithelial neoplasia

Most Recent Events

  • 03 Mar 2017 GlaxoSmithKline completes a phase III trial in Benign prostatic hyperplasia (Combination therapy) in China, Japan, South Korea and Taiwan (NCT02058368)
  • 31 Mar 2016 GlaxoSmithKline completes a phase III trial for Male sexual dysfunction (in patients with androgenetic alopecia) in Chile, Hong Kong, Singapore, Taiwan and South Korea(NCT02014584)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top